OncView™ Podcast: Advances in Systemic Therapy of Differentiated Thyroid Cancer
In an OncView™ program, Lori Wirth, MD, shared her insights into the current treatment of patients with differentiated thyroid cancer.
Facing Unmet Needs and Ongoing Trials in RR-DTC
Lori Wirth, MD, discusses the unmet needs and ongoing trials in development for patients with RR-DTC.
Treatment Options in RAI-refractory DTC in Second Line and Beyond
Lori Wirth, MD, discusses the role of cabozantinib in the second-line setting for patients with radioiodine-refractory differentiated thyroid cancer and reviews the results from the COSMIC-311 trial.
Frontline Treatment Options for RAI-refractory DTC
Lori Wirth, MD, defines radioiodine-refractory differentiated thyroid cancer and discusses frontline treatment options for patients with the disease.
Presentation and Disease Course of Differentiated Thyroid Cancer
Lori Wirth, MD, provides an overview of differentiated thyroid cancer including patient presentation and disease course.
2 Commerce Drive Cranbury, NJ 08512